WOCKPHARMA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 28/100 — Quality 42 · Valuation 1 · Growth 9 · Momentum 72
| Share price | ₹1,923.40 |
| Market cap | ₹22,130 Cr |
| P/B ratio | 4.8 |
| ROCE | 6.4% |
| Book value | ₹281.63 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹3,373 Cr | ₹199 Cr | 19.0% |
| 2025 | ₹3,012 Cr | ₹-57 Cr | 13.0% |
| 2024 | ₹2,798 Cr | ₹-472 Cr | 3.0% |
| 2023 | ₹2,651 Cr | ₹-621 Cr | 4.0% |
| 2022 | ₹3,230 Cr | ₹-279 Cr | 9.0% |
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafith